We found that anti-tumor immunity pathways, including cytokine production, chemokine signaling, TCR signaling, BCR signaling, and negative regulation of lymphocyte apoptosis, were significantly downregulated in the high-ADI group (51, 52). The gene discussed is BCR; the disease is neoplasm.